Komori
Annual Securities Report4263SUSMED,Inc.Information and Communication

Annual Securities Report — FY2025

What SUSMED,Inc. reported for the period from 2025-07-01 to 2026-06-30.

How much it says
67Detailed
What moved here
11named for the first time
Its own wording
62terms
Which filing this is
15/ 15newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

During the fiscal year ended June 2026, progress was made in the DTx product business, including the launch of sales of the “SusMed Medcle® app for insomnia disorder” following its receipt of insurance coverage on 1 June 2026, as well as the receipt of milestone payments under the co-development pipeline. An impairment loss was also recorded, partly because operating cash flow remained negative, and business revenue was ¥497.211 million, resulting in a net loss for the period of ¥382.691 million.

Komori's summary of this document, not the document's own words.
67Detailed
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
93
Very detailed
Magnitude of change
68
Detailed
Strategic shift
94
Very detailed
Capital movements
75
Very detailed
Disclosure Gaps
15
Almost nothing
Future commitments
68
Detailed
Change in Risk
55
Typical
Financial and Capital Policy
100
Very detailed
Specificity of disclosure
47
Typical
Product portfolio
55
Typical
Technology Position
50
Typical
Confidence in Strategic Bets
R&D spend2億円Money spent making new things.
Cash left over-5億円Cash from the business, less what went into equipment.
Spent on equipment2億円Plants, machines — things meant to last.
Employees50Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.
SUSMED,Inc. — FY2025 | Komori